The Societal Costs of Failing to Develop a Vaccine

BMJ
doi 10.1136/bmj.39269.490255.be
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Societal Costs Due to Meningococcal Disease: A National Registry-Based Study

ClinicoEconomics and Outcomes Research
Health PolicyEconomicsEconometricsFinance
2018English

Societal Costs of Diabetes Mellitus in Denmark

Diabetic Medicine
Internal MedicineEndocrinologyMetabolismDiabetes
2015English

The Lifetime Distribution of the Incremental Societal Costs of Autism

Archives of Pediatrics & Adolescent Medicine
2007English

Pricing Commercial Train Path Requests Based on Societal Costs

Transportation Research Part A: Policy and Practice
CivilManagement ScienceTransportationOperations ResearchStructural Engineering
2020English

Rebuttal to Peel Et Al. Re: ‘The Imperative to Develop a Human Vaccine for the Hendra Virus in Australia’

Infection Ecology and Epidemiology
EpidemiologyEnvironmental Science
2016English

Enriching the Evidence Base: Moving Towards Full Societal Costs and Benefits

BMC Health Services Research
Health Policy
2014English

Failing to Fail Nursing Students Among Mentors: A Confirmatory Factor Analysis of the Failing to Fail Scale

Nursing Open
Nursing
2019English

Study of the Immune Response in the Elderly: Is It Necessary to Develop a Vaccine Against Neisseria Meningitidis for the Aged?

Journal of Aging Research
GerontologyGeriatrics
2019English

Predictive Factors of High Societal Costs Among Chronic Low Back Pain Patients

European Journal of Pain
MedicineAnesthesiologyPain Medicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy